5 Stocks Raising The Drugs Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 3 points (0.0%) at 15,304 as of Thursday, May 23, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 979 issues advancing vs. 1,985 declining with 110 unchanged.

The Drugs industry currently sits up 0.3% versus the S&P 500, which is down 0.37. Top gainers within the industry include Forest Laboratories ( FRX), up 3.4%, and Bristol-Myers Squibb Company ( BMY), up 0.5%. A company within the industry that fell today was Regeneron Pharmaceuticals ( REGN), up 1.75.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Pharmacyclics Incorporated ( PCYC) is one of the companies pushing the Drugs industry higher today. As of noon trading, Pharmacyclics Incorporated is up $2.13 (2.59) to $84.48 on average volume Thus far, 365,025 shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 789,500 shares. The stock has ranged in price between $79.51-$85.28 after having opened the day at $81.26 as compared to the previous trading day's close of $82.35.

Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $6.2 billion and is part of the health care sector. The company has a P/E ratio of 73.2, above the S&P 500 P/E ratio of 17.7. Shares are up 46.6% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Pharmacyclics Incorporated as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share. Get the full Pharmacyclics Incorporated Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, Onyx Pharmaceuticals ( ONXX) is up $2.75 (2.96) to $95.78 on light volume Thus far, 426,206 shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $89.33-$96.61 after having opened the day at $92.01 as compared to the previous trading day's close of $93.03.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $6.8 billion and is part of the health care sector. Shares are up 23.0% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Onyx Pharmaceuticals Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Celgene Corporation ( CELG) is up $0.60 (0.49) to $124.04 on average volume Thus far, 1.4 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $120.55-$124.97 after having opened the day at $121.50 as compared to the previous trading day's close of $123.44.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $51.5 billion and is part of the health care sector. The company has a P/E ratio of 37.5, above the S&P 500 P/E ratio of 17.7. Shares are up 57.4% year to date as of the close of trading on Wednesday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Amgen ( AMGN) is up $1.01 (0.97) to $105.54 on light volume Thus far, 1.5 million shares of Amgen exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $103.00-$106.10 after having opened the day at $103.10 as compared to the previous trading day's close of $104.53.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $78.2 billion and is part of the health care sector. The company has a P/E ratio of 17.6, equal to the S&P 500 P/E ratio of 17.7. Shares are up 20.9% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Merck ( MRK) is up $0.38 (0.81) to $47.09 on average volume Thus far, 8.7 million shares of Merck exchanged hands as compared to its average daily volume of 16.9 million shares. The stock has ranged in price between $46.42-$47.19 after having opened the day at $46.46 as compared to the previous trading day's close of $46.71.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $142.9 billion and is part of the health care sector. The company has a P/E ratio of 24.1, above the S&P 500 P/E ratio of 17.7. Shares are up 14.1% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Merck a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null